Floatz logo

ibi310

Acral Melanoma That Has Been Removed by Surgery

Innovent Biologics (Suzhou) Co. Ltd.monoclonal_antibodyPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Acral Melanoma That Has Been Removed by Surgery cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Yonsei University
Phase 2BB
Rivoceranib
Peking University Cancer Hospital & Institute
Phase 3B
Nilotinib
Institute of Cancer Research, United Kingdom
Phase 2B
Nivolumab
Fred Hutchinson Cancer Center
Phase 2B
Imatinib
National Cancer Institute (NCI)
Phase 2B

View all 29 →

Same molecule, other indications

ibi310 is also rated in:

hepatocellular carcinomaDormant
B
Indicative ·
62 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
60 / 100
View asset →
MSI-HDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →